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ABSTRACT
Background
Hypertension is a common chronic disease, which is expensive to treat
and has serious but preventable long-term complications. It should be
possible to optimize antihypertensive therapy such that the most prevention is
obtained with the least cost. This optimization can be approached through
adherence to current national evidence-based practice guidelines for the
treatment of hypertension.
Objectives
The objectives of this study are: (1) to test hypotheses regarding
comorbidities and prescribing in hypertension and, (2) to identify opportunities
to improve adherence to treatment guidelines for hypertension.
Methods
The study employs a nonconcurrent cohort research design for
hypothesis testing in incident uncomplicated cases of hypertension . The
practice recommendations from the Joint National Committee on Prevention ,
Detection , Evaluation, and Treatment of High Blood Pressure were translated
into operational definitions of uncomplicated hypertension , relevant
comorbidities, and drug class prescribing . Administrative claims data were
used to classify cases with respect to diseases and classes. These
classifications were used to test for predicted disease-class associations.

Results
Multivariate adjusted odds ratios (OR) and 95% confidence intervals
(Cl) for significant associations include: Angiotensin Converting Enzyme
(ACE) inhibitor (5.88 OR, 2.57-13.43 Cl) and diuretic (10.87 OR, 4.70-25.15
Cl) prescribing positively associated with congestive heart failure ; betablocker (4.39 OR, 2.93-6.56 95% Cl) and calcium channel blocker (CCB) (2.70
OR, 1.88-3.86) prescribing positively associated with coronary artery disease;
beta-blocker prescribing negatively associated with chronic obstructive
pulmonary disease (0.50 OR, 0.33-0.75 Cl) and diabetes mellitus (0.56 OR,
0.38-0.82 Cl) ; and ACE inhibitor prescribing positively associated with
diabetes mellitus (1 .73 OR, 1.38-2.16 Cl). Additional significant associations
were found in bivariate analyses reported as unadjusted relative risks (RR)
and 95% confidence intervals (Cl) including: a positive association of ACE
inhibitor prescribing in renal failure (1.84 RR, 1.11-3.04 Cl) and negative
associations between diuretic (0.69 RR, 0.58-0 .83 Cl) and beta-blocker (0.62
RR, 0.50-0.77 Cl) prescribing with dyslipidemia . Diuretics and beta-blockers
(38.8%) are not used more frequently as first line therapy than CCBs and ACE
inhibitors (59.7%) in uncomplicated hypertension.
Conclusions
The predicted associations were largely confirmed, providing evidence
for appropriate prescribing in hypertension. Analysis of claims data can be a
useful method of measuring prescribing practices in hypertension. The details
of this methodology and its limitations are discussed. The major opportunity

for improvement relates to under-prescribing of diuretics and beta-blockers,
and over-prescribing of calcium channel blockers and ACE inhibitors in
uncomplicated hypertension.
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PREFACE
This dissertation was prepared in the format of the standard dissertation
plan . There is one manuscript divided into six sections. These include the
statement of the problem, introduction, methods, results, discussion, and
bibliography. Two appendices follow the manuscript. Tables appear at the
end of the body of the text.
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MANUSCRIPT

STATEMENT OF THE PROBLEM
The purposes of the study are to measure the influence of comorbid
medical conditions on the prescribing of antihypertensive drug therapeutic
classes and to identify opportunities for improvement in prescribing. It is
expected that known indications and contraindications influence the selection
of pharmaceutical classes for the treatment of hypertension. The magnitude
of this effect has not been estimated. A large administrative medical claims
database will provide a useful window into current prescribing practices. This
study will serve to identify opportunities for improvement in
pharmacotherapeutic aspects of hypertension management. The results will
be useful in efforts to improve selection of antihypertensive agents.

INTRODUCTION
Hypertension is a common chronic disease in adults with harmful
consequences that can be prevented with effective therapy. Hypertension is
treated by lifestyle modification and when necessary, pharmacologic therapy.
The goal of therapy is to reduce blood pressure without intolerably impairing
patients' quality of life. Individualization of therapy is important in reaching
optimal outcomes. Comorbid conditions, demographic variables , economic
considerations, side effect profiles, and patient preferences should influence
the individualization of therapy. There can be however, unexplained and even
undesirable influences on practice variation (Kaplan , 1994; Kaplan , 1998a).
The details of therapy are important to study because of their associated costs
and outcomes. It can be estimated that the wholesale costs for the top four
classes of anti hypertensive agents exceeded $5 billion in 1995 (Siegel and
Lopez, 1997). Heart disease and stroke are the first and third leading causes
of death in this country and are both associated with hypertension . The
financial burden alone for these illnesses has been estimated at over $259
billion in direct and indirect costs (JNC 6, 1997). For these reasons,
hypertension is a useful condition to study for the purposes of health care
quality improvement.
Health Care Quality Improvement
The health care delivery system in the United States is going through
rapid evolutionary change (Drake, 1997). The stimuli for these changes are
largely economic; however, issues of quality have started taking center stage
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(President's Advisory Commission on Consumer Protection and Quality in the
Health Care Industry, 1998). The concepts of Quality and Cost can be
combined , studied, and understood using the Health Care Value Equation
(Toscani, 1997):
Value

=Quality/Cost

It is useful to think about maximizing Value as the goal of our health care
delivery system. This can be accomplished by increasing Quality while
holding Cost constant or decreasing Cost while holding Quality constant.
Critics of managed care might argue that some managed care organizations
(MCO) are increasing Value by cutting Costs at the expense of smaller
reductions in Quality.
r
\

The modern practice of Health Care Quality Improvement (Jencks and
Wilensky, 1992) approaches the equation in a different way. Ideally, the goal
of health care quality improvement is to maximize Value by both increasing
Quality and decreasing Cost. This can be accomplished only through
systematic approaches to performance improvement. These systematic
approaches require frequent measurement for the purposes of identifying
opportunities for improvement, root cause analysis, design of interventions,
and evaluation of the interventions (Melum, 1995). Reliable, objective, low
cost measurement is essential to this method of performance improvement.
The models developed in this doctoral dissertation should be useful for
systematic efforts to measure and improve performance in the treatment of
hypertension. Such improved performance should increase Value as it relates

to the treatment of hypertension .
Hypertension has two sets of costs, those associated with treatment
and those associated with consequences of the disease. From a health
economic perspective, optimal Value occurs when we maximize the
prevention of long-term complications of hypertension while we minimize the
costs associated with treatment. Costs are relatively easy to quantify; quality
is more difficult.
Quality Measurement
Quality has been defined as "the degree to which health services for
individuals and populations increase the likelihood of desired health outcomes
and are consistent with current professional knowledge" by the Institute of
Medicine (Palmer, 1997). Donabedian proposed a framework for measuring
quality more than 30 years ago that still influences current thinking on these
issues (Donabedian, 1966). He suggested that data for quality measurement
should be classified according to the structures, processes, and outcomes of
care. The outcomes are the results or consequences of disease and health
services. These outcomes can include changes in health status (morbidity
and mortality) or more subjective measures (quality of life or functional status) .
The processes are the health services and other actions used to produce
outcomes. The structures are the people, places, and things used to deliver
those services and other actions. Modern quality science has largely moved
away from the earlier structural measures to those of outcomes and
processes . For performance improvement purposes, outcomes often take too
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long to occur and can be due to influences other than the processes under the
system 's control and statistical methods cannot always adjust for these
confounding influences. Therefore, process measurement has become the
more common method in quality improvement science. Systematic
performance improvement approaches focus primarily on processes and the
IOM definition of quality is primarily process oriented . At the level of
processes, quality can been more simply defined as doing the right things, and
doing them well (JCAHO, 1994).
The right things "increase the likelihood of desired health outcomes and
are consistent with current professional knowledge ." These principles call for
evidence of known process-outcome relationships with strong evidence bases
supporting them . In the absence of best evidence, expert consensus opinion
can suffice. These "right things" are currently defined by practice guidelines
with varying degrees of evidence supporting their recommendations . These
principles are also consistent with the growing movement called "Evidence
Base Medicine." One of the leaders of this movement describes: "Evidence
based medicine is the conscientious, explicit, and judicious use of current best
evidence in making decisions about the care of individual patients. The
practice of evidence based medicine means integrating individual clinical
expertise with the best available external clinical evidence from systematic
research . .. " (Kaplan, 1998a).
Peer reviewed literature can supplement the recommendations of
practice guidelines. Health care quality improvement science uses the

recommendations of practice guidelines, develops measurable indicators of
performance, and uses the results of such measurement to identify
opportunities for improvement. Objective measurement can be used to
develop interventions to improve performance on a system-wide basis.
Repeat measurements are used to evaluate the effects of targeted
interventions. To suit these purposes, measurement should be relatively
inexpensive and unobtrusive. The measures developed in this study should
meet those requirements. These measurements should be relatively
inexpensive because they will be derived from data already collected .
Expensive chart abstraction can be avoided. These measures should be
unobtrusive because the data collection occurs retrospectively and there is no
burden on the practitioners.
Guidelines
There are well accepted , evidence based guidelines for the treatment of
hypertension that are revised by a national panel of experts every four to five
years. This expert panel, the Joint National Committee on Prevention,
Detection , Evaluation, and Treatment of High Blood Pressure (JNC 5, 1994;
JNC 6, 1997) was brought together as part of the National High Blood
Pressure Education Program (NHBPEP) by the National Heart, Lung , and
Blood Institute (NHLBI) of the National Institutes of Health (NIH). The
continuing effort has lasted more than a quarter century. The reports of the
and

5th

committees are used in this study. The recommendations of the

5th

5th

report were used to create the quality indicators and the study interval (1994-
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1995) fell within the period after the 5th and before the 5th reports . The results
are discussed with respect to the recommendations of both the 5th and 5th
reports .
Epidemiology of Hypertension
Hypertension is the most prevalent disease in this country. affecting
approximately 50 million adults (28% of the adult population) when estimated
in 1988-1991 (Burt. Whelton, Roccella et al, 1995). Blood pressure increases
with age; the prevalence exceeds 50% at ages greater than or equal to 50
(Margolis and Klag , 1998). Most people will develop hypertension at some
time during their lives. Hypertension is the second most common reason for
visits to physicians in this country, more than 100 million annually (Kaplan.
1998c). Other risk factors for hypertension include race . obesity, diabetes
mellitus. and family history of hypertension (Burt et al, 1995; Margolis and
Klag . 1998).
Impact of Hypertension
Consequences of hypertension are important in terms of morbidity.
mortality, and health service costs. Sustained hypertension is associated with
higher overall mortality rate . stroke, myocardial infarction. and kidney disease
(Kaplan. 1998d). Morbidities associated with hypertension are expressed as
end organ damage of the heart. brain, kidneys, eyes, and blood vessels.
Heart disease associated with hypertension takes two forms , coronary
artery disease and congestive heart failure. Hypertension contributes toward
the progression of atherosclerotic disease and increases the workload on the

7

(

left ventricle. Atherosclerosis in the coronary arteries causes a decrease in
blood flow to the heart and can result in tissue ischemia, experienced as
symptomatic disease (angina), or tissue death (myocardial infarction). The
increase in workload on the left ventricle causes the heart muscle to
hypertrophy and eventually to fail (Levy, Larson , Ramachandran et al, 1996).
The heart is considered to be in failure when it can no longer pump an
adequate supply of blood to the vital organs.
The brain is effected by hypertension primarily by two pathophysiologic
processes, atherosclerotic disease and aneurysmal dilatation (Margolis and
Klag, 1998; Kaplan (1998d) . Hypertension contributes toward atherosclerotic
disease of the cerebrovascular system that can result in inadequate blood
supply to the brain. If the deficiency causes symptoms that are temporary, the
syndrome is called a transient ischemic attack (TIA) . If the deficiency results
in brain tissue death, it is called a stroke. Hypertension can cause rupture of a
cerebral aneurysm resulting in an intracerebral hemorrhage.
The kidneys are damaged by atherosclerotic disease of the large
arteries to the kidneys and by disease of the smaller arteries of the kidneys.
Kidney disease can lead to long term dialysis or kidney transplantation.
Kidney disease also contributes toward high blood pressure. Vision can be
impaired when hypertension causes damage to the small vessels of the eyes
(Kaplan, 1998d).
Vascular disease secondary to hypertension can take other forms .
Peripheral vascular disease (PVD) typically involves atherosclerosis of the

large vessels in the legs. The reduced blood supply can cause symptoms of
claudication (ischemic leg pain) and can cause tissue death. Treatment of
PVD often involves bypass surgery. Severe disease can lead to amputation .
Hypertension can cause weakening in vessel walls that can lead to rupture of
the vessel. The rupture of a large artery (e.g. aorta) results in a catastrophic
bleed (Kaplan, 1998d).
These consequences have costs in terms of human suffering and lost
productivity; however, these costs are difficult to measure. The costs of the
health services associated with these consequences are easier to measure.
These include professional services, hospitalization services, and medications.
Professional services include physicians and other health care provider
interventions. Hospitalization services include medical, surgical , and
rehabilitation interventions. Medications include the drugs used to treat the
consequences of hypertension. Precise measurement of these costs would
be important in assessing the overall Value in the treatment of hypertension.
Since this study focuses on quality, such precise cost estimates are beyond
the scope of this investigation. Just to place some of these costs in
perspective, hypertension is the second most common indication for physician
office visits and cardiovascular drugs are the most commonly prescribed
category of pharmaceutical agents (Woodwell, 1997).
Treatment of Hypertension
Hypertension can be successfully treated. Effective treatment lowers
risk for end organ damage and mortality (Kannel, 1996) (14). The treatment of
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hypertension includes lifestyle modification (Kaplan , 1998e) or nonpharmacologic therapy and the use of drugs when necessary (Kaplan , 1998a).
The goal of treatment is to lower blood pressure without intolerably impairing
the quality of life.
Lifestyle modification includes weight loss for people who are obese,
dietary change that can include a reduction in salt (TOMHS, 1991). calories
and alcohol, increasing physical activity and exercise, and smoking cessation
(Kaplan, 1998e).
For those patients who cannot lower their blood pressures with lifestyle
modification alone, pharmacologic therapy is necessary. There are more than
50 antihypertensive pharmacologic agents. These can be divided into major
classes. The five major classes include (Kaplan and Gifford , 1996): diuretics,
beta-blockers, calcium channel blockers (CCB). angiotensin converting
enzyme inhibitors (ACE inhibitors). and alpha-blockers. The prescription of
these five classes is the focus of this study.
Diuretics lower blood pressure by decreasing blood volume through the
elimination of sodium and water in the kidneys. They have the advantages of
lower cost and have been demonstrated to reduce long term consequences of
hypertension (JNC 6). The potential disadvantages include hypokalemia,
hyponatremia, hypomagnesemia, hyperuricemia, hypercalcemia ,
hyperlipidemia, glucose intolerance/insulin resistance, impotence, and
orthostasis (Kaplan and Gifford, 1996).
Beta blockers lower blood pressure by decreasing the heart rate and
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the force of contraction. They are advantageous for people with known
coronary artery disease since they have antianginal and antiarrhythmic effects.
The antianginal effects can reduce symptoms of ischemia. Beta blockers
prevent sudden death in patients who have had myocardial infarction
(Hennekens, Albert, Godfried et al, 1996). They have been demonstrated to
reduce long term consequences of hypertension . Their disadvantages include
side effects of insomnia , depressed mood , exercise intolerance, impotence,
and dyslipidemia. They can be particularly harmful to people with comorbid
congestive heart failure or asthma (Kaplan, 1998a).
Calcium channel blockers lower blood pressure by relaxing the muscles
in the arterial walls. They have advantages in their relatively benign side
effect profiles and can relieve symptoms of angina but have not been
demonstrated to reduce long term consequences of hypertension . They may
cause constipation, headaches, flushing, and ankle edema . Some calcium
channel blockers (those that decrease myocardial contractility) can be harmful
in congestive heart failure (Kaplan , 1998a).
Angiotensin converting enzyme inhibitors (ACE inhibitors) prevent the
formation of angiotensin, which has powerful vasoconstricting properties. This
mechanism lowers the blood pressure by dilating the blood vessels. These
agents have the advantages of being well tolerated and are particularly
beneficial to people with heart failure, renal damage (particularly diabetic
nephropathy) , and post myocardial infarction . However, they have not been
demonstrated to reduce the long-term consequences of hypertension alone.

II

The most common side effect is a dry cough (Kaplan, 1998a).
Alpha blockers lower blood pressure by inhibiting vasoconstrictive
nerve impulses . They have the advantages of a relatively benign side effect
profile and can reduce symptoms of prostate disease. They have not been
demonstrated to reduce long term consequences of hypertension . They can
cause severe orthostasis in the elderly and may cause urinary incontinence in
women .
Selection of Antihypertensive Agents
The treatment of hypertension has been extensively studied and
periodic evidence-based recommendations are made. The Joint National
Committee on Prevention, Detection , Evaluation, and Treatment of High Blood
Pressure (JNC) issues these recommendations every four to five years. The
recommendations from the last two reports have been used in this study for
reasons cited above. In summarizing the recommendations pertinent to this
study the following points must be made: 1) the JNC VI largely upheld the
recommendations of the JNC V, as they relate to this study; 2) the reports
recommend that diuretics and beta blockers should be used as first line agents
because they have been proven to reduce morbidity and mortality; and 3) drug
therapy should be tailored to the individual needs of patients taking into
consideration such factors as age, race , comorbid conditions, lifestyle, and
economic status. The effect of comorbid conditions on the selection of
hypertensive classes is the primary subject of this study. Some examples
were alluded to in the description of the five major classes , above. Important
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comorbid conditions that were selected for this study include: dyslipidemia,
coronary artery disease, congestive heart failure , diabetes mellitus, renal
failure , prostatic hypertrophy, and chronic obstructive pulmonary disease. Age
and gender are potentially important demographic variables that should
influence class selection (JNC 5, JNC 6, Kaplan , 1998a).
Despite the recommendations of the JNC it has been demonstrated that
CCB and ACE inhibitor prescribing are increasing while diuretic and betablocker prescribing are decreasing (Kaplan , 1994, Siegel and Lopez, 1997).
Until very recently (Mehta, Wilcox, and Schulman, 1999), published studies
had not been able to associate prescribing with disease states that should
influence selection of particular classes of agents. This study will address this
important gap in the literature.
Therapeutic class associations with comorbidities can be divided into
three categories: compelling indication for use; may have favorable effect on
comorbidity; and , may have unfavorable effect on comorbidity (JNC 6). The
first two categories can be considered preferred agents. The third category
can be considered less preferred agents. Preferred agents should be
expected to be used for the treatment of hypertension in patients with the
given comorbidity or demographic risk factor more often than for the treatment
of hypertension in patients without the comorbidity or risk factor. Less
preferred agents should be expected to be used for the treatment of
hypertension in patients with the given comorbidity or demographic risk factor
less often than for the treatment of hypertension in patients without the
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comorbidity or risk factor. The relationships should be strongest where
compelling indications exist.
Measurement Methodology
Administrative claims data have been recommended as an appropriate
source for pharmacoepidemiologic research and specifically for the purposes
of measuring health care quality (lezzoni, 1997; Quam et al, 1993). The
advantages of using this source of data include: 1) data collection costs are
relatively low since the data are already available in electronic form; 2) studies
using these data are unobtrusive to providers and patients; 3) the claims
database can provide a population-based , longitudinal record, across
treatment sites; and 4) these data are not adversely influenced by patient
recall biases. The disadvantages include: 1) diagnosis and treatment
information may be incomplete; 2) the validity of data elements is often not
well established ; and 3) the data were not collected primarily for the purpose
of study.
Claims data have been used to identify patients with hypertension and
the validity of this method of measurement has been studied and compared to
other methods of identification (Quam et al, 1993). Investigators looked at 3
methods of claims based identification and compared them with chart review
and patient survey data. The study population consisted of patients from two
independent practice association health plans that contracted with
independent practitioners who billed discounted fee-for-service to the plans.
The two study years were calendar years 1988 and 1989. For all three
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methods, patients with specific comorbidities were excluded from analysis.
The first claims based method focused specifically on diagnosis codes , the
second utilized pharmacy claims , and the third method used a combination of
pharmacy and diagnosis data. The diagnosis-based definition required at
least one claim within a two year time period using any of ICD-9-CM codes
401 , 401.0 , 401.1 or 401.9 and specifically excluded those with pharmacy
claims for antihypertensive medications. The pharmacy-based definition
requ ired at least one prescription for an antihypertensive agent without any
diagnosis codes (above) for hypertension. These two sets of criteria were
designed to be mutually exclusive and to identify patients without specific
comorbidities. The combined definition required both a diagnosis code and a
claim for an antihypertensive agent. Patients were classified as hypertensive
by the survey method if they answered positively when asked if a doctor ever
told them that they have hypertension or high blood pressure. Patients were
classified as hypertensive by the medical chart review method if they: (1 ) had
hypertension or a synonym listed as a current or historical problem ; (2) they
had two measured elevated blood pressure readings recorded on the most
recent office visits; or (3) antihypertensive therapy was listed and there was at
least one recorded measurement of elevated blood pressure.
Initial analysis revealed approximately 50% agreement between the diagnosisbased and prescription-based definitions and both the medical record-based
and survey-based definitions. The diagnosis-based definition, when modified
to require two diagnosis codes in the time interval, performed much better,
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agreeing with medical record-based definition almost 75% of the time.
The use of administrative medical claims data has been compared with
a survey methodology in the identification of patients with diabetes mellitus
and heart disease (O'Connor, Rush , Pronk, and Cherney, 1998). These
investigators found that 2 codes for diabetes mellitus in a 2-year period yielded
a sensitivity and specificity of 0.91 and 0.99 respectively with a positive
predictive value of 0.94. For heart disease these investigators looked for one
code in a defined one-year period of time. This strategy yielded sensitivity,
specificity, and positive predictive values of 0.89, 0.99, and 0.85 respectively.
The heart diseases that were of interest in this study included congestive heart
failure , history of myocardial infarction , angina, and arteriosclerotic
cardiovascular disease. It was recogn ized from previous work that in diabetes
mellitus, a one code requirement leads to false identification of patients.
Use of administrative claims data, has typically been used in the inpatient setting (lezzoni, 1997) but has been increasingly used in the
ambulatory setting. Pharmaceutical therapy prescribing was studied using a
similar measurement methodology for ambulatory patients with diabetes
mellitus (Glauber and Brown, 1992).
The results of these studies were used to determine the strategy used
in the current study. It was decided that two codes would operationally define
hypertension and the relevant comorbidities since false positive rates can be
high with a one code requirement. It was anticipated that the associated
decrease in sensitivity and potential decrease in sample size would not be a
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problem using the large population covered by the database that was acquired
for this study.
Hypotheses
In incident uncomplicated cases of hypertension specific comorbidities
should influence the prescribing of antihypertensive drug classes. Positive
associations should be observed between ACE inhibitors and diuretics in
congestive heart failure and between beta-blockers and CCBs in coronary
artery disease. ACE inhibitors should be positively associated with diabetes
mellitus and renal insufficiency, particularly in diabetic nephropathy. Alpha
blockers should be positively associated with benign prostatic hypertrophy.
Negative associations should be observed between beta-blockers in chronic
obstructive pulmonary disease, congestive heart failure , diabetes mellitus, and
dyslipidemia. Negative associations should be observed for CCBs in
congestive heart failure and diuretics in dyslipidemia.
In incident cases of uncomplicated hypertension without relevant
comorbidities (congestive heart failure, coronary artery disease, chronic
obstructive pulmonary disease, diabetes mellitus, renal insufficiency,
dyslipidemia, and benign prostatic hypertrophy) diuretics and beta-blockers
should be prescribed as first line agents.
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METHODS
Research Design
The study employs a nonconcurrent cohort research design to test
hypotheses concerning class prescribing in the presence and absence of
relevant comorbidities. This longitudinal design focuses on prescribing that
occurs only after the diagnoses of relevant comorbidities have been made.
Patient Population
Data for analysis were obtained from the claims database of a large
Blue Cross and Blue Shield plan through a contract with the nonprofit Hawaii
Medical Service Association Foundation 1 . This plan is the largest provider of
health care coverage in the state of Hawaii. Of the 1.1 million insured in
Hawaii this plan covers 53%. Hawaii's population is ethnically diverse.
Roughly a third of the population is white , over 60% are Asian or Pacific
Islander. The remaining 5% are split among black, American Indian , and other
races . Of the Asian or Pacific Islanders, over 22% are Japanese, over 15%
are Filipino, over 12% are Hawaiian, and over 6% are Chinese. The
remaining 7.5 % are split among Korean , Vietnamese, Samoan, and other.
Over 7% of the population living in Hawaii are of Hispanic origin. The health
system in Hawaii is similar to that of other US states with two important
exceptions: 1) health care coverage in Hawaii is nearly universal since
employers are required to provide coverage to all half-time and full-time

' The HMSA Foundation is a private grantmaking charity affiliated with HMSA. Its primary
activities include grantmaking, research , education and community service publications.
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employees; and 2) there is almost no migration beyond the islands (Hawaii
Medical Services Association Foundation , 1995). These characteristics make
this population particularly useful for epidemiological study. Potential cases
for study included patients in the fee-for-service plan with a diagnosis of
hypertension at any time during calendar years 1994 through 1996.
Database
The Blue Cross and Blue Shield database included three files : the
pharmacy file , the medical file , and the demographics file. These files were
linked using an unique patient identification code without revealing the actual
identity of individuals.
Pharmacy claims data included individual drug generic names,
therapeutic class codes , dispense date, supply, and units. Generic names and
therapeutic class codes from the pharmacy file were used to identify
therapeutic class utilization. A patient was classified to have used the
therapeutic class if he/she received an agent from that class at least once
during the study interval; cases in which the first occurrence of class
prescribing preceded the first date of diagnosis were eliminated . Medical
claims data included diagnosis codes, procedure codes , dates of service,
place of service, provider and specialty identifiers. ICD-9 CM codes (HCFA,
1994) from the medical claims file were used to determine the presence of
hypertension and target comorbidities (Table 1). The demographics file
included birth date, gender, dates in the plan , and type of plan.
The data were obtained in flat file format, however, the size of the data
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base required normalization . This was accomplished in Microsoft Access for
Windows 95 , Version 7.0. Preliminary data cleaning and initial univariate
analyses were performed using Microsoft Access prior to univariate, bivariate,
and multivariate statistical analyses being performed using the SAS System
for Windows, Release 6.11 . Output from SAS analyses were manually
entered into Microsoft Excel spreadsheets for additional manipulation and
display. The results of Excel analyses appear in tables in the body of the text.
Data Cleaning
Patients without any ICD-9 CM code for hypertension were eliminated .
Range checks were performed on age, gender, and visit frequency. Nonsense values on these variables were identified and associated patients
eliminated from analyses. In addition, a gender by diagnosis search was
performed to identify any potential erroneous combinations (e.g. women with
benign prostatic hypertrophy). Those identified (11 cases) were also
eliminated from analyses. Frequencies of diagnoses over time and
prescription use over time were used to evaluate for inconsistencies in the
database.
Disease Definitions
Prevalent cases of hypertension and relevant comorbidities were
operationally defined by the presence of two or more codes from a target set
of ICD-9 CM codes , specific to hypertension or the relevant comorbidity, in a
given patient, on two or more visits, within the three calendar years 19941996. These target sets of codes appear in Table 1. Incident cases of
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uncomplicated hypertension were operationally defined in the same manner
with an additional requirement that they have a one-year period free of
antihypertensive drug therapy prior to the index diagnosis and that they have
no coded complications of hypertension. The index diagnosis is defined as
the first appearance of a target diagnostic code within the three calendar
years. A subset of cases for the incident, uncomplicated cases of
hypertension were identified who had no defined relevant comorbidities. This
subset were chosen to look at class prescribing in the groups of patients most
likely to be following the JNC recommendations for first line therapy in
uncomplicated hypertension .
Alternative strategies for operationally defining prevalent cases were
explored. The effects of these strategies on potential sample sizes are
summarized in Appendix A.
Pharmacologic Class Definitions
A patient was classified as having been prescribed a pharmacologic class if
there was at least one appearance of a drug from that class in the pharmacy
file . The first date of fill for an agent in each class was identified. Those dates
were used to determine the order of class prescribing in the treatment
regimens. When combination agents were used or two classes were initiated
on the same date, both classes were assigned that order in the regimen . The
first date of fill for each class was used to establish the temporal relationship
between diagnoses of relevant comorbidities and the prescribing of classes
predicted to be influenced by those diagnoses. In bivariate analyses, cases in
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which the first occurrence of class prescribing preceded the first date of
diagnosis were eliminated . The presence of comorbidities and pharmacologic
classes were coded as one. Their absence was coded as zero.
Univariate Analyses
Frequencies were obtained for ICD-9 CM codes, unique patients with
ICD-9 CM codes, unique patients with specific comorbities, unique patients
dispensed specific pharmacologic agents, and unique patients dispensed
pharmacologic classes. A patient was classified as having been dispensed
the class if there was at least one prescription filled from that class in the
period of investigation , regardless of when that occurred .
Bivariate Analyses
Bivariate analyses were performed using 2 X 2 tables from the FREQ
procedure in SAS Version 6 (SAS, 1995) to evaluate the associations of the
relevant comorbities with the dispensing of pharmacologic agents using Chisquare and Fisher's exact test. In order to ensure that comorbidities were
known prior to the prescribing decision, only cases in which the relevant
comorbidities preceded prescribing of the associated classes were included in
th is set.
Multivariate Analyses
Backward elimination logistic regression analyses (SAS, 1995b) were
performed to evaluate the independent effects of comorbidities and
demographic risk factors on the dispensing of specific drug classes. The
models for these logistic regression analyses used diuretic (DI), beta blocker
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(BB) , calcium channel blocker (CCB), angiotensin converting enzyme inhibitor
(ACEI) , and alpha blocker (AB) as outcome variables and used age, sex, and
diagnosis of congestive heart failure (CHF), dyslipidemia (LIP), coronary artery
disease (CAD) , chronic obstructive pulmonary disease (COPD), benign
prostatic hypertrophy (BPH), diabetes mellitus (OM), and renal failure (KID) as
predictor variables. All nine predictor variables were entered into the model
before backward elimination of variables with significance levels greater than
0.01. This conservative significance level was chosen because of the large
number of observations and to compensate for the use of multiple models.
The logistic regression models appear below.
Model
Model
Model
Model
Model

1:
2:
3:
4:
5:

Dl=CHF LIP BPH CAD COPD OM KID Age Sex
BB*= LIP BPH CAD COPD OM KID Age Sex
CCB=CHF LIP BPH CAD COPD OM KID Age Sex
ACEl=CHF LIP BPH CAD COPD OM KID Age Sex
AB*= LIP BPH CAD COPD OM KID Age Sex

*The beta blocker and alpha blocker models failed to converge. CHF was
eliminated due to the small numbers of observations in these two models.
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RESULTS
The results of univariate, bivariate, and multivariate analyses performed
using SAS were manually transferred into Microsoft Excel for additional
calculations and display. These results are summarized in tabular form in the
body of the text.
Univariate Analyses
A total of 32,322 cases met the definition of prevalent hypertension . Of
those, 4,871 met the definition of incident, uncomplicated hypertension. Of the
4,871 cases with incident, uncomplicated hypertension, 2,405 had no relevant
comorbid ities.
The frequencies and proportions of cases with demographic
characteristics and relevant comorbidities within the prevalent cases of
hypertension and the incident, uncomplicated cases of hypertension appear in
Table 2. Frequencies and proportions of individuals dispensed specific drug
classes appear in Table 3.
Of the cases with no relevant comorbidities (Table 4) 58.8% did not fill a
prescription for antihypertensive pharmacotherapy. Of those filling a
prescription for antihypertensive pharmacotherapy, almost two thirds were
treated with one class of therapy alone. Less than one fourth received either a
diuretic or a beta-blocker as the lone therapeutic class. Over 40% received
another lone therapeutic class. Diuretics and beta-blockers were each
prescribed as the first class in therapy almost 20% of the time. Calcium
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channel blockers and ACE Inhibitors were each prescribed as the first class in
therapy approximately 30% of the time. Alpha-blockers were prescribed as
the first class in therapy less than 2% of the time.
The order of therapeutic class in the treatment regimens is displayed in
Table 5. Among cases with any comorbidies, the first class in the regimen
was most frequently a calcium channel blocker (32%) followed by ACE
inhibitors (29%), diuretics (18%), beta blockers (17%), and alpha blockers
(3%). The second class in the regimen was most frequently an ACE inhibitor
(30%) followed by calcium channel blockers and diuretics (each at 25%) , beta
blockers (19%), and alpha blockers (2%) . Diuretics were the most commonly
prescribed third line agents (32%) followed by ACE inhibitors and calcium
channel blockers (each at 26%), beta blockers (11 %), and alpha blockers
(5%) . Fourth line therapy occurred very infrequently.
Among cases with no comorbidities, first line therapies were most
frequently calcium channel blockers (31%), followed by ACE inhibitors (29%) ,
diuretics and beta blockers (each at 19%), and alpha blockers (2%). Second
line therapy was most commonly an ACE inhibitor (28%), followed by calcium
channel blockers (27%), diuretics (26%), beta blockers (18%), and alpha
blockers (2%). Third line therapy was most commonly an ACE inhibitor or
diuretic (each at 29%), followed by calcium channel blockers (26%), beta
blockers (10%), and alpha blockers (6%).
In benign prostatic hypertrophy, alpha blockers were prescribed as first
line therapy in 23% of cases but ranked only third behind calcium channel
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blockers and ACE inhibitors (each at 26%). Beta blockers were first line
therapy in 13% of cases followed by diuretics (12%). Second , third , and fourth
line therapies were infrequent.
In chronic obstructive pulmonary disease, calcium channel blockers
were the class most frequently prescribed as first line therapy (32%) followed
by ACE inhibitors (30%) , diuretics (22%), beta blockers (10%), and alpha
blockers (5%). As second line therapy ACE inhibitors were most frequently
prescribed (35%) followed by calcium channel blockers (29%), diuretics (19%),
beta blockers (14%), and alpha blockers (4%). Third and fourth line therapies
were infrequent.
Congestive heart failure was an infrequent comorbidity. Diuretics were
used most commonly as first line therapy (55%) followed by ACE inhibitors
(32%) and calcium channel blockers (14%).
In coronary artery disease, calcium channel blockers were the class
most frequently prescribed as first line therapy (42%) followed by beta
blockers (26%), ACE inhibitors (21%), diuretics (9%), and alpha blockers (2%).
Second line therapy was most frequently a beta blocker (42%) followed by
calcium channel blockers (35%) and ACE inhibitors (23%). Third and fourth
line therapies were infrequent.
In dyslipidemia, calcium channel blockers were the most frequently
prescribed first line therapy (33%) followed by ACE inhibitors (30%), diuretics
(18%), beta blockers (15%), and alpha blockers (4%). ACE inhibitors were the
most commonly prescribed second line therapy (32%) followed by diuretics
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(23%), calcium channel blockers and beta blockers (each at 22%), and alpha
blockers (2%). Third line therapy was most frequently a calcium channel
blocker (34%) followed by diuretics (31 %), ACE inhibitors (20%), beta blockers
(9%). and alpha blockers (6%).
In diabetes mellitus ACE inhibitors were the most frequently prescribed
first line therapy (46%) followed by calcium channel blockers (32%). diuretics
(27%), and beta blockers (9%). ACE inhibitors were also most commonly
prescribed as second line therapy (29%) followed by calcium channel blockers
(27%). diuretics (24%). beta blockers (15%). and alpha blockers (6%) .
Renal insufficiency was an infrequent comorbidity. ACE inhibitors were
most commonly prescribed as first line therapy (40%) followed by diuretics
(35%), calcium channel blockers (15%), beta blockers and alpha blockers
(each at 5%) .
Bivariate Analyses
Unadjusted Risk Ratios (RR) and 95% Confidence Intervals (Cl) for
selected bivariate relationships are displayed in Table 6. Statistically
significant RRs are evident where Cls do not include one.
Beta-blocker prescribing was positively associated with coronary artery
disease and negatively associated with chronic obstructive pulmonary
disease. diabetes mellitus and dyslipidemia. Of the cases with coronary artery
disease, more than 22% filled a prescription for a beta blocker while those
without coronary artery disease filled such a prescription less than 9% of the
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time. These proportions yielded a risk ratio of 2.56 with a 95% confidence
interval of 1.85-3.56 . Of the cases with chronic obstructive pulmonary disease
less than 5% filled a prescription for a beta blocker while almost 10% of cases
without chronic obstructive pulmonary disease filled such a prescription .
These proportions yielded a RR of 0.47 with Cl 0.31-0.71. Less than 5% of
patients with diabetes mellitus filled a prescription for a beta blocker while
almost 10% without diabetes filled such a prescription . These proportions
yielded a RR of 0.44 with Cl 0.28-0.67. Cases with dyslipidemia filled a
prescription for a beta blocker 6% of the time while those without dyslipidemia
filled such a prescription almost 10% of the time. These proportions yielded
RR 0.62 with Cl 0.50-0.77.
Coronary artery disease was also positively associated with calcium
channel blocker prescribing. Cases with coronary artery disease filled
prescriptions for beta blockers more than 27% of the time while those without
coronary artery disease filled such prescriptions less than 16% of the time.
These proportions yielded RR 1.77 with Cl 1.33-2 .36.
ACE Inhibitor prescribing was positively associated with diabetes
mellitus and renal failure . ACE inhibitor prescriptions were filled by patients
with diabetes mellitus in over 20% of cases. Less than 15% of cases without
diabetes mellitus filled such prescriptions. These proportions yielded RR 1.41
with Cl 1.17-1.70. ACE inhibitor prescriptions were filled by patients with renal
failure in more than 28% of cases. Less than16% of cases without renal
failure filled such a prescription. These proportions yielded RR 1.84 with Cl
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1.11 -3.04.
Like beta blockers, diuretics were negatively associated with
dyslipidemia. Less than 8% of cases with dyslipidemia filled a prescription for
a diuretic while more than 11 % of those without dyslipidemia filled such a
prescription. These proportions yielded RR 0.69 with Cl 0.58-0.83.
Congestive heart failure was positively associated with diuretic
prescribing . Almost half of the cases with congestive heart failure filled a
prescription for a diuretic while slightly more than 10% of those without
congestive heart failure filled such a prescription. These proportions yielded a
risk ratio (RR) of 4.58 with a 95% confidence interval (Cl) of 2.83-7.42. Benign
prostatic hypertrophy was positively associated with alpha-blocker prescribing .
Almost 9% of cases with benign prostatic hypertrophy filled a prescription for
an alpha blocker while only !% without benign prostatic hypertrophy filled such
a prescription . The relationships between congestive heart failure and
diuretics and between alpha blockers and benign prostatic hypertrophy,
although statistically significant, have questionable validity due to small cell
sizes.
Multivariate Analyses
Multivariate Adjusted Odds Ratios (OR) and Confidence Intervals (Cl)
from logistic regression analyses appear in Table 8. In the diuretic model ,
congestive heart failure (10.87 OR, 4.70-25.15 Cl) and female gender (0.55
OR, 0.45-0.66 Cl) were positively associated.
In the calcium channel blocker model, only coronary artery disease was
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positively associated (2.70 OR, 1.88-3 .86 Cl) . In the ACE Inhibitor model both
congestive heart failure (5.88 OR, 2.57-13.43 Cl) and diabetes mellitus (1 .73
RR, 1.38-2.16) were positively associated.
The beta blocker and alpha blocker models failed to converge with all
nine variables entered initially. Because of the small numbers of congestive
heart failure cases (23) this variable was eliminated from the beta blocker and
alpha blocker models. Chronic obstructive pulmonary disease (0.50 OR, 0.330.75 Cl) , diabetes mellitus (0.56 OR, 0.38-0.82 Cl), and male gender (0.64
OR, 0.52-0.78 Cl) were negatively associated with beta blocker prescribing
while coronary artery disease was positively associated (4 .39 OR, 2.93-6.56
Cl) . Benign prostatic hypertrophy (6.02 OR, 3.50-10.36 Cl), older age (0 .39
OR, 0.20-0.75 Cl), and male gender (2.33 OR, 1.26-4.30 Cl) were positively
associated with alpha blocker prescribing .
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DISCUSSION
This section will start with a discussion of the hypotheses and
systematically progress from review and comments on the results of the
specific analyses, through explanations of findings consistent with , and
findings seemingly inconsistent with , predicted directional relationships .
Limitations and practical applications will round out the discussion .
Recommendations will be made regard ing future measurement efforts and
opportunities for improvement in antihypertensive class selection will be
identified.
Predictions were based on the assumption that preferred agents would
be associated with positive risk factors and less preferred agents would be
associated with negative risk factors in confirmatory bivariate analyses. The
positive risk factors should have Risk Ratios greater than one. The negative
risk factors should have Risk Ratios less than one. The confidence intervals
for these measures of association should not include one. Significant positive
relationships should be observed for the following : ACE inhibitors and diuretics
in congestive heart failure , ACE inhibitors in diabetes mellitus and renal failure ,
beta-blockers and CCBs in coronary artery disease, and alpha-blockers in
benign prostatic hypertrophy. Significant negative relationships should exist
for the following : beta-blockers in chronic obstructive pulmonary disease,
congestive heart failure, dyslipidemia, and diabetes mellitus, CCBs in
congestive heart failure, and diuretics in dyslipidemia.
Since beta-blockers and diuretics are preferred for uncomplicated

31

hypertension we should observe a higher proportion of prescribing of these
agents than CCBs and ACE Inhibitors in cases without relevant comorbidities.
Predicted significant positive relationships were observed for diuretic
and ACE inhibitor prescribing in congestive heart failure , beta-blocker and
CCB prescribing in coronary artery disease, and ACE inhibitor prescribing in
diabetes mellitus and renal failure . Predicted significant negative relationships
were observed for beta-blocker prescribing in diabetes mellitus, chronic
obstructive pulmonary disease, and dyslipidemia. Alpha blockers were
positively associated with benign prostatic hypertrophy but in both the bivariate
and logistic regression models the validity of this finding is questionable due to
small numbers of observations. ACE Inhibitors and diuretics were found to be
positively associated with congestive heart failure in the logistic regression
model but not in the bivariate analyses.
Predicted negative relationships that were not observed include betablocker and CCB prescribing in congestive heart failure. The absence of the
predicted observations in congestive heart failure may be partially due to the
availability of new drugs in these classes that are potentially beneficial in this
disease. In addition, there were few observations in these comorbidities such
that interpretation of findings within these conditions is difficult.
In the cases with no relevant comorbidities, treated with
pharmacotherapy, only one quarter were treated with diuretics or betablockers as the lone class of therapy. Other lone classes of therapy were
prescribed in 40% of these cases. When looking at first class in the
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therapeutic regimen , CCBs and ACE Inhibitors account for 60% while diuretics
and beta blockers account for only 40%. Adherence to guidelines would have
been demonstrated by greater prescribing of the preferred classes than the
unpreferred classes.
There were a number of interesting findings from the order of
therapeutic class data. Calcium channel blockers and ACE inhibitors appear
to be preferred over diuretics and beta blockers as first line therapy. That
preference does not appear to depend greatly upon the presence of
comorbidities. The cases without relevant comorbidities do receive beta
blockers and diuretics more frequently than the cases with comorbidities
however the difference is very small (1-2%) . Diuretics are used in increasing
proportions as the number of classes in the regimen increases. This is true for
both cases with and cases without comorbidities. Alpha blockers are
infrequently prescribed and appear to have a significant role only in first line
therapy for men with benign prostatic hypertrophy. Even in that group, ACE
inhibitors and calcium channel blockers are prescribed more frequently than
alpha blockers. Beta blockers appear less frequently as first line therapy in
chronic obstructive pulmonary disease and diabetes mellitus than in cases
without comorbidities. ACE inhibitors seem to be preferred in renal
insufficiency and diabetes mellitus.
Limitations
This measurement model was able to confirm the vast majority of the
predicted associations. However, potential applications of these results must
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be weighed against important methodological and theoretical limitations.
The use of administrative claims data is advantageous because they
are relatively inexpensive and unobtrusive to obtain. However, an important
limitation of using the automated health plan databases for research is the lack
of information on potential confounders. In prescribing for hypertension these
potential confounders include: race , patient preference, and history of previous
therapeutic trials. In this study the effect of history of previous therapeutic
trials was addressed by creating the ideal group of incident, uncomplicated
cases of hypertension. Race and patient preferences were not accessible in
this data base.
Another potential limitation stems from the reliance on dispensing data
for attribution of prescribing practices. Prescribing could have occurred but if
the patients did not fill the prescriptions then the prescribing was not counted.
In the present study, 58% of incident, uncomplicated cases with no relevant
comorbidities did not fill any prescriptions for antihypertensive therapy. It is
not known how many of these had prescriptions given and not filled or
prescriptions not given . It is also important to recall that not all hypertension
needs to be treated with pharmacotherapy. A trial of lifestyle modification is
suggested , prior to instituting pharmacotherapy. This study dealt with this
potential limitation by focusing primarily on the patients who used
pharmacotherapy. There should only be a problem in interpreting relative
prescribing of classes if patients were less likely to fill prescriptions for some
classes compared to others. This question is beyond the scope of this
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investigation.
Another potential limitation has to do with the generalizability of the
findings to other populations . Hawaii is different from other states in its
relative geographic isolation and in the racial and ethnic composition of its
population. These differences should not influence prescribing practices since
the same risks and benefits apply to the different races and ethnic groups.
There may however, be a cultural difference in the filling of prescribed
therapies. If Hawaiians are less likely to fill prescriptions than Americans in
other states then the magnitudes of proportions would be lower in this study
than if studied in the continental United States. The relative measures of
prescribing should not be influenced by such a cultural difference however.
Future studies should attempt to measure these effects in other states and in
other practice and payer models.
Another potential limitation of this study stems from the use of multiple
tests and comparisons. This strategy can lead to the identification of spurious
relationships. These finding should be confirmed in an independent sample.
It is also worth noting that the alpha blocker and beta blocker logistic
regression models did not converge until congestive heart failure was
removed. The decision to remove congestive heart failure from these models
was based upon the small number of cases with congestive heart failure . This
is not surprising given that hypertension is a major risk factor for congestive
heart failure and there should be very little congestive heart failure in a
population with incident hypertension. Since the calcium channel blocker,
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ACE inhibitor, and diuretic models did converge with congestive heart failure
included , this condition was not removed from these models. It was
particularly important to look at congestive heart failure in the diuretic and ACE
inhibitor models since this condition is considered a compelling indication for
the use of these classes of therapy.
Coded claims can introduce a potential systematic bias in classification
of comorbidities and drug prescribing . The use of a diagnostic code can be
made in error and the filling of a prescription can be made in error. By
insisting on at least two codes for the definition of comorbidities this study
should have reduced the probability of falsely including cases with the relevant
comorbidities. By accepting any dispensing of an antihypertensive agent as
defining the prescribing this study could have falsely identified some class
prescribing . Future investigations should explore the use of other drug
prescribing definitions.
Measurement Issues
The measurement strategy used in this study was sufficient to
demonstrate expected relationships among comorbidities and antihypertensive
classes. Subsets of comorbidities should have more specificity and therefore
might show larger effect sizes. Future studies should explore the use of more
specific subsets (e.g. left heart failure , diabetic nephropathy) in a larger
population (e.g. prevalent cases of hypertension). A structural model could
incorporate known causal relationships among diseases, demographic and
therapeutic variables. It might also be useful to look at specialist-generalist
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comparisons and high volume provider-low volume provider comparisons to
further validate the measures.
Practical Applications
The study examined the association between population-based , plan
level, antihypertensive prescribing and comorbidities. Compelling indications
appear to influence prescribing as do conditions for which there may be
favorable or unfavorable effects of certain classes of agents. It can also be
safely stated that diuretics and beta-blockers are not treated as preferred
agents in uncomplicated hypertension as recommended .
Opportunities For Improvement in Prescribing
Opportunities for improvement in prescribing can be classified as
problems of underutilization or overutilization. Since the JNC continues to
recommend diuretic and beta-blockers as first line agents for uncomplicated
hypertension we need to look at the relative utilization of these agents
compared to other classes. These preferred classes rank third and fourth
behind CCBs and ACE inhibitors. This can be interpreted as underutilization
of these preferred classes or overutilization of the more popular but less
preferred (according to evidence/guidelines) classes for the treatment of
uncomplicated hypertension . The second area to look at relates to what the
JNC is now calling compelling indications. These compelling indications are
based upon randomized controlled clinical trials and were the source of many
of the predicted relationships in this study. These compelling indications
include: ACE inhibitors for diabetic nephropathy, ACE inhibitors and diuretics
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for heart failure, and beta-blockers for post myocardial infarction . The
numbers of observations within these comorbidity sets was too low for
meaningful quantitative conclusions. These conditions are expected to be
uncommon in incident cases of uncomplicated hypertension. A future study
should attempt to quantify these relationships in prevalent cases of
hypertension where these important comorbidities have been demonstrated to
be more prevalent (Table 2).
Conclusions
Administrative claims data can be successfully used to measure
prescribing practices in hypertension. Comorbidities influence prescribing in
hypertension as outlined in Joint National Commission guidelines. However,
diuretics and beta blockers are not preferred over calcium channel blockers
and angiotensin converting enzyme inhibitors as first line therapy in
uncomplicated hypertension , despite the significant evidence base that
supports this practice.
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Table 1. ICD-9 CM• code sets for operational definitions of prevalent cases of
hypertension and relevant comorbidities: broad definitions

Hypertension
Patients with ICD-9 CM codes for hypertension: 401 .x, 402.xx, 403.xx, 404.xx, and
405.xx
Coronary Artery Disease
Patients with ICD-9 CM codes for Myocardial Infarction, lschemic Heart Disease,
Angina , or Coronary Atherosclerosis: 410.xx, 411 .xx, 412, 413.x, 414, 414.0, 414.8,
and 414.9
Congestive Heart Failure
Patients with ICD-9 CM codes for Heart Failure: 428.x, 402.x1 , 404.x1 , and 404.x3
Diabetes Mellitus
Patients with ICD-9 CM codes for Diabetes Mellitus: 250.xx
Chronic Obstructive Pulmonary Disease
Patients with ICD-9 CM codes for Asthma , Chronic Bronchitis, Emphysema,
Bronchitis Not Specified as Acute or Chronic, and Chronic Airway Obstruction Not
Elsewhere Classified: 490, 491 .xx, 492.x, 493.xx, and 496.
Benign Prostatic Hypertrophy
Patients with ICD-9 CM code for BPH: 600
Dyslipidemias
Patients with ICD-9 CM codes for Disorders of Lipoid Metabolism or Hyperlipidemias:
272.x
Kidney Disease
Patients with ICD-9 CM codes for Renal Failure, Nephrotic or Nephritic Disorders,
Hypertensive Renal Disease, or Diabetic Nephropathy: 581 .x, 582.xx, 583.xx, 584 .x,
585 , 586, 587 , 403.xx, 404.xx, and 250.4x

* HCFA (1994)
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Table 1. (Cont.) ICD-9 CM• code sets for operational definitions of prevalent cases of
hypertension and relevant comorbidities : specific subsets
Hypertension. Uncomplicated Essential (Specific Subset of Hypertension)
Patients with ICD-9 CM codes for Essential, Benign Essential, and Unspecified
Essential Hypertension: 401 , 401 .1, and 401 .9 without ICD-9 CM codes for Malignant
Hypertension, Hypertensive Heart Disease, Hypertensive Renal Disease, or
Secondary Hypertension: 401 .0, 402.xx, 403.xx, 404.xx, and 405.xx
Hypertension, Uncomplicated Essential Incident Cases (Specific Subset of
Hypertension)
Patients classified as Uncomplicated Essential Hypertension in whom the first
appearance of the ICD-9 CM code for Hypertension is preceded by a one year period
free of anti-hypertensive pharmacotherapy.
Post Myocardial Infarction (Specific Subset of Coronary Artery Disease)
Patients with ICD-9 CM codes for Myocardial Infarction, Post Myocardial Infarction
Syndrome, or Old Myocardial Infarction: 41 O.xx, 411 .0, and 412
Left Heart Failure (Specific Subset of CHFl
Patients with ICD-9 CM codes for Left Heart Failure: 428.1
Hypertensive Heart Disease with Congestive Heart Failure (Specific Subset of CHFl
Patients with ICD-9 CM codes for Hypertensive Heart Disease with CHF: 402.x1,
404.x1 and 404.x3
Asthma (Specific Subset of COPD)
Patients with ICD-9 CM codes specific to Asthma : 493.xx

* HCFA (1994)
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Table 1. (Cont.) ICD-9 CM• code sets for operational definitions of prevalent cases
of hypertension and relevant comorbidities: specific subsets
Type 1 Diabetes Mellitus (Specific Subset of OM)
Patients with ICD-9 CM codes for Diabetes Mellitus Type 1: 250.x1
Hypertensive Renal Disease (Specific Subset Kidney Disease)
Patients with ICD-9 CM codes for Hypertensive Renal Disease: 403.xx and 404.xx
Diabetic Nephropathy 1 (Specific Subset of Kidney Disease and DMl
Patients with ICD-9 CM codes for Diabetes Mellitus with Renal Manifestation or
Diabetes Mellitus and Chronic or Unspecified Renal Failure: 250.4x, 250.xx and (585
or 586)
Diabetic Nephropathy 2 (More Specific Subset of Kidney Disease and DMU
Patients with ICD-9 CM codes for Diabetes Mellitus with Renal Manifestations: 250.4x
Other Renal Disease (Specific Subset of Kidney Disease)
Patients with ICD-9 CM codes for non-hypertensive and non-diabetic renal diseases:
581.xx, 582.xx, 583.xx, 584.x, 585, and 586 , 587

• HCFA (1994)
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Table 2. Frequencies and (proportions) of demographics & relevant comorbidities in
prevalent cases of hypertension and incident. uncomplicated cases of hypertension

Prevalent
Hypertension
N = 32,322
2548 (7.9)

Incident.
Uncomplicated
Hypertension
N =4,871
237 (4.9)

15,422 (47 .8)

2343 (48.1)

Chronic Obstructive Pulmonary
Disease
Asthma

3695 (11.4)

514 (10.6)

1991 (6.2)

269 (5.5)

Benign Prostatic Hypertrophy

2808 (8.7)

282 (5.8)

Older Age (>64)
Female

...s

-'-

Coronary Artery Disease

2934 (9.1)

...':.. ..o:_
141 (2.9)

Post Myocardial Infarction

501 (1 .6)

25 (0.5)

15442 (47 .8)

1834 (37.7)

Congestive Heart Failure
Left Heart Failure

915 (2 .8)

23 (0 .5)

91 (0 .3)

Hypertensive Heart Failure

130 (0.4)

2 (0)
0 (0)

Dyslipidemia

5936 (18 .4)

Diabetes Mellitus
Type 1 Diabetes Mellitus

651 (2.0)
1029 (3.2)

Renal Failure
Diabetic Nephropathy (Def 1)

225 (0.7)

515(10.6)
34 (0.7)
41 (0.8)
3 (0.1)

Diabetic Nephropathy (Def 2)

398 (1 .2)

Hypertensive Renal Failure

363 (1 .1)

8 (0.2)
0 (0)

Other Renal Failure

816 (2.5)

38 (0.8)

Diabetic Nephropathy definitions in Table 1.
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Table 3. Frequencies and (proportions) of patients dispensed drug classes in
prevalent cases of hypertension and in incident, uncomplicated cases of hypertension

Drug
Class

Prevalent
Hypertension
(N = 32,322)

Diuretic

8346 (25.8)

Incident,
Uncomplicated
Hypertension
J_N = 4,87!2_
514 (10.6)

Beta-Blocker

6834 (21 .1)

446 (9 .2)

CCB

13248 (41 .0)

787(16.2)

ACEI

10683 (33.1)

755 (15 .5)

Alpha-Blocker

1430 (6.7)

74 (1 .5)

ARB

1430 (4.4)

143 (2 .9)

Sympatholy1ic

1447 (4.5)

51 (1 .0)

Vasodilator

381 (1 .2)

3 (0.1)

CCB = Calcium Channel Blocker
ACEI = Angiotensin Converting Enzyme Inhibitor
ARB= Angiotensin II Receptor Blocker
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Table 4. Antihypertensive drug classes dispensed in incident, uncomplicated cases
with no relevant comorbidities•

Frequencies
and
(Proportions)
of Total Cases
(N=2405)

Frequencies and
(Proportions) of
those Dispensed
Antihypertensive
Drug(s) (N=991) ••

No Drug_
Diuretic
Beta-blocker
CCB
ACE Inhibitor
A!e_ha-blocker

1414 58.81
272j 11 .31
246 10.2
390 16.2
368 15.3
68J:2.! [

0 Ol
272 27.4
246 24.8
390 39.4
368J:371

Diuretic alone
Beta-blocker
alone
CCB alone
ACE Inhibitor
alone
Alpha-blocker
alone

92J:3.! [
129 (5 .4)

Diuretic
Beta-blocker
CCB
ACE Inhibitor
AIQha-blocker

68J:6~

9iI9 :t_
129 (13.0)

21619~
181 (7 .5)

216J:21 .! [
181 (18.3)

9 (0.4)

9 (0.9)

Frequencies and (Proportions)
as First Class in Therapy
J_N=102"Q ••
199l19.4[
199l19.4[
319131.1}_
294_(28.6}_
16_i1 .6}_

• Cases with incident, uncomplicated hypertension without any of the following
comorbidities : coronary artery disease, congestive heart failure, chronic obstructive
pulmonary disease, dyslipidemia, diabetes mellitus, renal failure, and benign prostatic
hypertrophy.
•• N's don't match due to 36 ties for first class in therapy.
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Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated
cases of hypertension

Order Diuretic

CCB

ACEI

Beta
Block
Freg_

% Freg_

%

Freg_

17 648
19 117
11 20
33 2

32
25
26
22

595
140
20
0

%

Alpha
Block
Freg_

%

29
30
26
0

61
9
4
0

3
2
5
0

Freg_

%

1
2
3
4

371
115
24
4

18
25
32
44

347
88
8
3

None

1
2
3
4

199
61
9
3

19
26
29
60

199
43
3
1

19 318
18 63
10 8
20 1

31
27
26
20

294
65
9
0

29
28
29
0

16
4
2
0

2
2
6
0

BPH

1
2
3
4

12
7
1
0

12
32
33
0

13
5
0
0

13
23
0
0

26
23
67
0

27
3
0
0

26
14
0
0

24
2
0
0

23
9
0
0

Any_

27
5
2
0

=

Any
Any Comorbidities
None = No Comorbidities
BPH = Benign Prostatic Hypertrophy
CCB = Calcium Channel Blocker
ACEI
Angiotensin Converting Enzyme Inhibitor

=
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Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated
cases of hypertension
Beta
Block

Orde Diuretic
r
Fr~

Alpha
Block

ACE/

CCB

59

%
30

Fr~

63

%
32

Fr~

20

%
10

Fr~

43

%
22

Fr~

1

10

%
5

2
3
4

10
3
0

19
30
0

7
0
0

14
0
0

15
1
1

29
10
100

18
5
0

35
50
0

2
1
0

4
10
0

CHF

1
2
3
4

12
0
1
0

55
0
50
0

0
0
0
0

0
0
0
0

3
2
0
0

14
33
0
0

7
4
1
0

32
67
50
0

0
0
0
0

0
0
0
0

CAD

1
2
3
4

8
0
3
0

9
0
50
0

24
11
0
1

26
42
0
100

38
9
0
0

42
35
0
0

19
6
3
0

21
23
50
0

2
0
0
0

2
0
0
0

COP
D

COPD
CHF
CAD
CCB
ACE/

= Chronic Obstructive Pulmonary Disease
=Congestive Heart Failure
= Coronary Artery Disease
= Calcium Channel Blocker
= Angiotensin Converting Enzyme Inhibitor
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Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated
cases of hypertension

Order Diureti
Beta
c
Block
Freg_ % Freg_

Freg_

%

Alpha
Block
Freg_

LIP

1
2
3
4

128
38
11
1

18 108
23 36
31
3
33 1

15 235 33
22 37 22
9 12 34
33 1 33

212
53
7
0

30
32
20
0

31
3
2
0

4
2
6
0

DM

1
2
3
4

27
13
6
0

12
24
67
0

20
8
2
1

9 70
15 15
22 0
100 0

32
27
0
0

101
16
1
0

46
29
11
0

1
3
0
0

0
6
0
0

KID

1
2
3
4

7
1
0
0

35
13
0
0

1
0
0
0

15
38
0
0

8
4
1
0

40
50
100
0

1
0
0
0

5
0
0
0

LIP
DM
KID
CCB
ACEI

%

5
0
0
0

CCB

ACEI

Fregj %

3
3
0
0

= Dyslipidemia
= Diabetes Mellitus
=Renal Insufficiency
= Calcium Channel Blocker
= Angiotensin Converting Enzyme Inhibitor
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Table 6. Unadjusted risk ratios and confidence intervals for selected bivariate
relationships in incident, uncomplicated cases of hypertension

Congestive
Heart Failure

Proportion
with Risk
Factor on
Class

Proportion
without
Risk Factor on
Class

Risk
Ratios

Diuretic

47.37

10.33

4.58

2.83 - 7.42.
+

Coronary
Artery
Disease
Beta-Blocker
CCB

22.22
27.69

8.67
15.64

2.56
1.77

1.85 - 3.56.
1.33-2.36*

Diabetes
Mellitus
Beta-Blocker
ACE Inhibitor

4.16
20.60

9.53
14.62

0.436
1.41

0.28- 0.67.
1.17-1 .70*

Renal Failure
ACE Inhibitor

28.21

15.36

1.84

1.11 - 3.04 .

lo.47

I0.31 - 0.71 •

0.58- 0.83.
0.50- 0.77.

~eta-Blocker

(95%)

ICOPD

14.51

19.62

Confidence
Intervals

Dyslipidemia
Diuretic
Beta-Blocker

7.59
6.07

11 .06
9.81

0.69
0.62

8.90

1.05

8.51

Benign
Prostatic
f:!yQ_ertr~

AlphaBlocker

5.33 - 13.58 •
+

CCB = Calcium Channel Blocker
Angiotensin Converting Enzyme
ACE
COPD =Chronic Obstructive Pulmonary Disease
Confidence Interval Does Not Include 1
Questionable Validity Due to Small Number of Observations
+

•

=
=
=
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Table 7. Adjusted odds ratios and confidence intervals from logistic regression
analyses in incident, uncomplicated cases of hypertension
Diuretic Model
Dl=COPD BPH CAD LIP CHF OM KID Age Sex
Variables
CHF
Male

Odds Ratios
10.87
0.55

Confidence Intervals
J_Wald, 95°/~
4.70- 25.15
0.45 - 0.66

Calcium Channel Blocker Model
CCB=COPD BPH CAD LIP CHF OM KID Age Sex
Odds Ratios
Variables
CAD

2.70

Confidence Intervals
(Wald , 95%)
1.88 - 3.86

ACE Inhibitor Model
ACEl=COPD BPH CAD LIP CHF OM KID Age Sex
Odds Ratios
Variables
CHF
OM

5.88
1.73

Confidence Interval
(Wald , 95%)
2.57 - 13.43
1.38-2.16

COPD = Chronic Obstructive Pulmonary Disease
CAD= Coronary Artery Disease
CHF =Congestive Heart Failure
BPH =Benign Prostatic Hypertrophy OM= Diabetes Mellitus
KID= Renal Failure
LIP= Dyslipidemia
Older Age = Age >64
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Table 7. Adjusted odds ratios and confidence intervals from logistic regression
analyses in incident, uncomplicated cases of hypertension
Beta Blocker Model
BB=COPD BPH CAD LIP OM KID Age Sex
Odds Ratios

Confidence Intervals
(Wald , 95%)

0.50
4.39
0.56
0.64

0.33- 0.75
2.93-6.56
0.38-0.82
0.52 - 0.78

Variables
COPD
CAD
OM
Male

Alpha-Blocker Model
AB=COPD BPH CAD LIP OM KID Age Sex
Odds Ratios

Confidence Intervals
(Wald, 95%)

6.02
0.39
2.33

3.50 -10.36
0.20-0 .75
1.26-4.30

Variables
BPH
A_g_e
Male

COPD = Chronic Obstructive Pulmonary Disease
CAD= Coronary Artery Disease
CHF =Congestive Heart Failure
BPH =Benign Prostatic Hypertrophy OM= Diabetes Mellitus
KID= Renal Failure
LIP= Dyslipidemia
Older Age = Age >64

• CHF eliminated from beta blocker and alpha blocker models due to small numbers
of observations
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Appendix A: Alternatives for Operational Definitions of Prevalent Cases

Various operational definitions for prevalent cases were considered and
tested for their effects on potential sample size. These operational definitions
varied in two different dimensions: the number of required occurrences of the
target ICD-9 CM codes and the duration of the interval during which codes
must appear.
The first dimension varied from one code in the time interval, to two
codes , to three codes. The second dimension varied in the duration of the
time interval from index diagnosis date plus one year, to index diagnosis date
plus two years, to the entire three calendar years. The index diagnosis date
was the date on which the first diagnosis code from the respective comorbidity
set appeared in the claims history.
The table (below) shows the frequencies and proportions of
observations, in a 50% random sample, meeting the various comorbidity
definitions for the number of codes required and duration of the interval.
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Table. Operational Definitions of Prevalent Cases of Hypertension and
Relevant Comorbities, according to number of codes required and time
interval for observing the codes, with frequencies and (proportions) reported .
N=19,707 from a 50% random sample

Prevalent Cases of
H_ye_ertension
Index diagnosis+ 1_yr
Index di'!ll_nosis + 2_yr
1994-1996

3 Codes (GE)

2 Codes (GE)

1 Codes (GE)

11,811J:59.9}
13,488_{_68.1_2_
13,839J,_70.21

14,916175.f l
15,912 (80.D_
16 , 080_{_81.~

19, 70711
19,707_{_100)
19, 707 _{_1 OQ2_

Incident,
Uncomplicated Cases
of H...1'2_ertension
Index di'!ll_nosis + 1_1'.!:
Index di'!ll_nosis + 2E
1994 - 1996

3 Codes (GE)

2 codes (GE)

1 Codes (GE)

9,263_{_47.QL
10,648J:54.<IT
10,945155.!&

12,016_{_61.QL

16,535 _{_83 .9)

BPH
Index dia nosis + 1 r
Index dia nosis + 2 r
1994 - 1996

LIP
Index di'!ll_nosis + 1_1'.!:
Index di'!ll_nosis + 2_yr
1994 - 1996

3 Codes_{_GEl
5,596_{_28.'!2._
6,860134.l[
7,143_{_36.~

BPH
LIP
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ocIT

12,864165.~

16 , 535183 . ~

13,011]_66.Qi

16,535183.91

2 Codes (GE
1,123 5.7
1,484 7.5
1,540 7.8

1 Codes (GE
2,751 14.0
2,751 14.0
2,751 14.0

2 Codes_{_G~
7 ,898 _{_40 .1_2_
8,739144
8,892 _{_451_2_

1 Codes1GE)

3I

11 , 531_{_58 . ~

11,531~8.~
11,531 (58.5)

Table. Operational Definitions of Prevalent Cases of Hypertension and
Relevant Comorbities, according to number of codes required and time
interval for observing the codes , with frequencies and (proportions) reported.
N=19,707 from a 50% random sample

CAD
Index dia nosis + 1
Index dia nosis + 2
1994 - 1996

Ml

1994 - 1996

CHF
Index Dia nosis + 1
Index Dia nosis + 2
1994 - 1996

LHF

1994 - 1996

HHF

1994 - 1996

CAD
Ml
CHF
LHF
HHF

= Coron'!!Y_ Art~ Disease
= Post M__y_ocardial Infarction
= Co~estive Heart Failure
= Left Heart Failure
= H_i'j'.l_ertensive Heart Failure
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Table. Operational Definitions of Prevalent Cases of Hypertension and
Relevant Comorbities, according to number of codes required and time
interval for observing the codes , with frequencies and (proportions) reported .
N=19 ,707 from a 50% random sample

COPD
Index Dia nosis + 1 r
Index Dia nosis + 2 r
1994 - 1996

1 Codes GE
3,884 19.7
3,884 19.7
3,884 19.7

ASTH
Index Dia nosis + 1 r
Index Dia nosis + 2 r
1994 - 1996

DM
Index Dia nosis + 1 r
Index Dia nosis + 2 r
1994 - 1996

DMT1
Index Dia nosis + 1 r
Index Dia nosis + 2 r
1994 - 1996

COPD
ASTH
DM
DMT1

= Chronic Obstructive Pulmona_!l'_ Disease
=Asthma
= Diabetes Mellitus
= Diabetes Mellitus TyJJ_e 1
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Table _ Operational Definitions of Prevalent Cases of Hypertension and
Relevant Comorbities, according to number of codes requ ired and time
interval for observing the codes , with frequencies and (proportions) reported _
N=19,707 from a 50% random sample

KID

1994 - 1996

HRF

1994 - 1996

ORF
Index Dia nosis + 1
Index Dia nosis + 2
1994 - 1996

KID
DMNe h1
DMNe h2
HRF
ORF
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Appendix B. Abbreviations Of Comorbidity Clusters And Drug Classes

COPD
ASTH
BPH
LIP
CAD
Ml
CHF
LHF
HHF
OM
DMT1
KID
DMN~h1

DMNeQh2
HRF
ORF
DI
BB
CCB
ACEI
AB
ARB
SY
VD

= Chronic Obstructive Pulmona_!Y Disease
=Asthma
= Benign Prostatic H_l'f)_eJE!asia
=~~demia

= Coronan--_ ArtEllY_ Disease
= Post M_.Y.ocardial Infarction
= Co~estive Heart Failure
= Left Heart Failure
= t:!.w_ertensive Heart Failure
= Diabetes Mellitus
= Diabetes Mellitus T_}IE)_e 1
= Renal Failure
= Diabetic N~hrqE_at~Definition
= Diabetic N~hr~tt}y{Definition ~
= t:!.w_ertensive Renal Failure
= Other Renal Failure
=Diuretics
= Beta Blockers
= Calcium Channel Blockers
= A~otensin Converti~ En~me Inhibitors
= A.!E_ha Blockers
= A~otensin Rec~or Blockers
= ~m_Q_atho_Mi_cs
= Vasodilators

IT
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